Status:
ACTIVE_NOT_RECRUITING
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
Prostate Cancer Foundation
Conditions:
Metastatic Malignant Neoplasm in the Prostate Gland
Prostate Carcinoma
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in pa...
Detailed Description
PRIMARY OBJECTIVE: I. To define the biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues of patients with prostate cancer. SECONDARY OBJECTIVES: I. To evaluate whether 68Ga-FAPi-46 ...
Eligibility Criteria
Inclusion
- Patients who underwent a 68Ga-PSMA-11 PET/CT scan within 3 months of enrollment
- Patients who are scheduled to undergo surgical excision or biopsy of a prostate cancer primary, recurrent or metastatic lesion
- Patients can provide written informed consent
- Patients are able to remain still for duration of imaging procedure (up to one hour)
Exclusion
- Patients with any new prostate therapy between the PSMA PET/CT and the FAP inhibitor (FAPI) PET/CT
Key Trial Info
Start Date :
September 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04457232
Start Date
September 9 2020
End Date
May 30 2026
Last Update
July 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095